Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Denali Therapeutics

Request full access

Discover and develop medicines to defeat neurodegeneration

South San Francisco, United StatesFounded 2015Biotech & Life Sciences

About Denali Therapeutics

Denali Therapeutics is a biotechnology company focused on discovering and developing treatments for neurodegenerative diseases, such as Alzheimer's, Parkinson's, and ALS. These diseases are characterized by the progressive degeneration of nerve cells, leading to severe physical and cognitive impairments. Denali's mission is to defeat these debilitating conditions through rigorous scientific research and innovative therapeutic development.

The company operates in the highly specialized field of neurodegenerative disease treatment, targeting a market that includes patients, healthcare providers, and pharmaceutical partners. Denali Therapeutics employs a scientific approach that leverages advances in genetics, pathology, and cell biology to identify pathways that cause neurodegeneration. By understanding these pathways, Denali aims to develop molecular therapeutics—drugs designed to interact with specific molecules in the body to treat diseases.

Denali's business model is built on a combination of in-house research and strategic partnerships. The company collaborates with other biotech firms, research institutions, and pharmaceutical companies to access new technologies, scientific insights, and potential therapeutic assets. This collaborative approach not only accelerates the discovery and development process but also spreads the financial risk associated with drug development.

Revenue is primarily generated through the development and commercialization of its therapeutic products. This includes licensing agreements, milestone payments from partners, and eventual sales of approved drugs. By focusing on high-impact neurodegenerative diseases, Denali aims to create treatments that significantly improve patient outcomes, which in turn drives demand and financial performance.

In summary, Denali Therapeutics is a biotech company dedicated to combating neurodegenerative diseases through scientific discovery and strategic partnerships. It serves patients, healthcare providers, and pharmaceutical partners, operating in a niche but critical market with a collaborative and research-driven business model.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2017

Denali Therapeutics in the South San Francisco ecosystem

Live from Dealroom

The Denali Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

Series B and later3 investors entered at this stage

Employees mapped 598 incl. 9 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 11 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$95M

104 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Denali Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.